Clinical Trial Update: Y-4 to Treat the Postherpetic Neuralgia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Y-4 for postherpetic neuralgia is currently recruiting. The study is sponsored by Neurodawn Pharmaceutical Co., Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postherpetic Neuralgia

Drugs mentioned

• Y-4

Snippet

Sponsor: Neurodawn Pharmaceutical Co., Ltd. | Conditions: Postherpetic Neuralgia, Y-4 | Phase 2 | Status: RECRUITING